

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Close
Treatment Agent: Atezolizumab
Synopsis: The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone. The addition of atezolizumab to the usual chemotherapy could prevent or reduce the chances of your cancer from returning, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the study drug would need to demonstrate increased chances of survival without the tumor returning by 10% or more compared to the usual approach.
Close
Inclusion Criteria:
For women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required; a female of childbearing potential is a sexually mature female who:
No known active hepatitis B or C
Active hepatitis B can be defined as:
Active hepatitis C can be defined as:
Excluded if known active pulmonary disease with hypoxia defined as:
Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following:
Close
Close
Interested in a
Clinical Trial?